ClinicalTrials.gg
TerminatedNCT03658720Updated Sep 5, 2018

Nurofen Ibuprofen Orodispersible Tablet Disintegration Study

An interventional study of 200 mg Ibuprofen acid orodispersible tablet in Healthy, sponsored by Reckitt Benckiser Healthcare (UK) Limited. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-05.

Sponsored by Reckitt Benckiser Healthcare (UK) Limited (part of Reckitt) · Not applicable, Interventional, and Other

Why this study was terminated
Study was not feasible as designed to allow for appropriate completion

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2017, registered Apr 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Disintegration time is an important quality attribute of ODTs, and the evaluation of disintegration time is positioned as a key step in formulation development, manufacturing, and clinical practice. The standard recommended over-the counter dose of 200mg Nurofen ibuprofen ODT is one (200mg) to two (400mg) tablets. To reflect this, the disintegration time of both one (200mg) and two (400mg) tablets will be assessed in this study.

Studies have been performed assessing in vivo ODT disintegration time and have created standardised oral conditions by giving water prior to dosing, to moisten/wet the mouth. In this study it is therefore necessary to standardise the oral conditions as much as possible, despite the interpersonal variability, to measure the time it takes for the ODT to disintegrate. For this study, 20 mL of water is swallowed prior to dosing to standardise oral conditions. Thirty-three healthy volunteers are required to be randomised into the study, to allow evaluable data to be obtained for 30 subjects. Subjects are given a light meal/snack and then fast for 2 hours 15 minutes (± 15 minutes) before dosing, in order to bring the oral cavity environment as close as possible to standard levels and to minimise variability in salivation. Directly before dosing, subjects drink (with oral cavity rinsing) 20 mL of water. Subjects are dosed according to the sequence they have been randomised and the ODT disintegration time assessed.

Following the first dose, subjects complete a washout period of a minimum of 4 hours, in accordance with the recommended posology, before receiving the second dose. During this washout period, subjects are given a second light meal/snack (the same as the previous light meal/snack), timed to allow subjects to fast for 2 hours 15 minutes (± 15 minutes) before the second dose. Directly before the second dose, subjects drink (with oral cavity rinsing) 20 mL of water. Subjects then receive the alternative dose to the dose they received during the first assessment, in accordance with the randomisation sequence.

Following completion of the disintegration assessments, or upon subject withdrawal, subjects are asked whether they are experiencing any symptoms or complaints. Any AEs are recorded in the CRF and followed up as necessary by the Investigator. Subjects then leave the clinic.Subjects are contacted by the Investigator (or designee) from 24 to up to 48 hours to ensure any AEs are captured.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Reckitt Benckiser Healthcare (UK) Limited is the lead sponsor of 35 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects who have given written .
  2. Age: ≥ 18 years ≤ 50 years.
  3. (BMI) of ≥ 18.5 and ≤ 30 kg/m2.
  4. Healthy as determined by past medical history, physical examination and vital signs at screening.

Exclusion criteria

Exclusion Criteria:

  1. A history of allergy or intolerance (including angioedema, urticaria, bronchospasm, reflux symptoms and rhinitis) related to treatment with ibuprofen, aspirin or other NSAIDs, or the of the formulations.
  2. A history (treated or untreated) of an oral condition affecting salivation and mouth dryness (e.g. dry mouth, hypersalivation)
  3. A history of hepatic or renal impairment, hepatic dysfunction, cardiovascular disease, cerebrovascular problems or high blood pressure.
  4. A history of asthma.
  5. A history of peptic or duodenal ulcers or upper gastro-intestinal bleed, or other significant gastro-intestinal disorders (including gastro-oesophageal reflux symptoms or gastritis) ulceration, perforation or haemorrhage.
  6. A history of coagulation disorder or susceptibility to bleeding
  7. A current or recent (within 2 months) oral issue, which in the opinion of the Principal Investigator could interfere with the study (e.g. mouth ulcers, aphthous ulcers, herpetic disease, oral candidiasis, burning mouth syndrome, geographic tongue, oral swellings, sores or lesions.
  8. Those currently suffering from dehydration
  9. A current or history of oral piercing.
  10. A current or recent history (within one year of the study) of alcohol abuse or significant abuse/misuse of any legal or illegal drugs, substances and solvents
  11. Those with a positive screen/test for drugs of abuse and/or alcohol
  12. Those who consume more than 14 units of alcohol per week, and where this consumption is spread over less than 3 days, or those who regularly (weekly) consumed excessive amounts of alcohol (>8 units for men and >6 units for women in one consumption, excessive amounts as defined by the UK National Office of Statistics)
  13. Those who had consumed alcohol within the 24 hours before enrolment onto the study.
  14. Those who had regularly consumed excessive quantities of caffeine (>6 cups of tea, coffee or cola per day), according to the Investigator's judgment.
  15. Those who had consumed caffeine-containing food and drinks within the 24 hours before enrolment onto the study.
  16. Those who had performed strenuous exercise within the 24 hours before enrolment onto the study.
  17. Those who currently or have recently (within last 6 months) use/d tobacco or nicotine containing products.
  18. Those who have used any herbal/vitamin or fish oil supplement in the 7 days prior to enrolment
  19. Those who have used any OTC or prescription medications (except hormonal ) in the 7 days prior to enrolment
  20. Those who have used ibuprofen with concomitant aspirin or other NSAIDs including cyclooxygenase-2 selective inhibitors and any drugs that should be used with caution, in combination with ibuprofen as per the SmPC, in the 7 days prior to enrolment (or longer if stated within the SmPC)
  21. Those previously randomised into this study.
  22. Those who are an employee at the study site.
  23. Those who are a partner or first-degree relative of the Investigator or other employees.
  24. Those who have participated in any taste testing study within 3 days of the screening visit.
  25. Those who have participated in a clinical trial involving consumption of an medicinal product within 3 months of dosing or a study with a marketed compound in the last month before dosing.
  26. Those unable in the opinion of the Investigator to comply fully with the study requirements.
  27. Women who are pregnant or breast feeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Single tablet

    Ibuprofen acid ODT: 1x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.

    Drug: 200 mg Ibuprofen acid orodispersible tablet

  • Experimental
    Two tablets

    Ibuprofen acid ODTs: 2x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.

    Drug: 200 mg Ibuprofen acid orodispersible tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Tablet disintegration time

    Time to complete tablet disintegration in seconds

    Time frame: Time of dosing to complete disintegration of the tablet being achieved (2 doses; single assessment day)

Secondary outcomes

  1. Number of Adverse Events

    Time frame: Up to follow up (24-48 hours after assessment day)

07

Study locations

1 site
  • Simbec Reseach Limited
    Merthyr Tydfil, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Dec 2017, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2018
First posted
Sep 5, 2018
StartActual
Dec 19, 2017
Primary completionActual
Dec 21, 2017
CompletionActual
Dec 21, 2017
Last update
Sep 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03658720
Collaborators
Simbec Research
Responsible party
Sponsor
First posted
Sep 5, 2018
Start date
Dec 19, 2017
Primary completion
Dec 21, 2017
Completion
Dec 21, 2017
Last update
Sep 5, 2018

Study contacts

Clinical Research Director, Clinical Research
study director · Reckitt Benckiser Healthcare (UK) Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion